Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ferring Bravelle in vitro use

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Ferring's Bravelle (urofollitropin) is approved for use in in vitro fertilization Dec. 19. The human-derived follicle-stimulating hormone was shown to similar efficacy to genetically engineered FSH in two trials of patients undergoing controlled ovarian hyperstimulation for IVF. The studies found comparable pregnancy outcomes for Bravelle and Follistim (recombinant follitropin beta), with significantly less injection site pain, Ferring said. Bravelle was approved May 6, 2002, for ovulation induction following pituitary suppression (Pharmaceutical Approvals Monthly, June 1, 2002, In Brief). Ferring is also touting Bravelle as the lowest priced product in its categor

You may also be interested in...

CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach

Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.

Submitting A Non-COVID-19 Product For FDA Review? Then Take A Seat, It’s Gonna Be Awhile

Top US FDA device center officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts